Alnylam Pharmaceuticals
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 220m | 493m | 844m | 1.0b | 1.8b | 2.2b | 2.6b |
| % growth | 193 % | 124 % | 71 % | 23 % | 76 % | 23 % | 14 % |
| EBITDA | (939m) | (771m) | (709m) | (894m) | (107m) | - | - |
| % EBITDA margin | (427 %) | (156 %) | (84 %) | (86 %) | (6 %) | - | - |
| Profit | (886m) | (858m) | (853m) | (1.1b) | (440m) | - | - |
| % profit margin | (403 %) | (174 %) | (101 %) | (109 %) | (24 %) | - | - |
| R&D budget | 655m | 655m | 792m | 883m | 1.0b | - | - |
| R&D % of revenue | 298 % | 133 % | 94 % | 85 % | 55 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$15.5m | Series B | ||
$24.6m | Early VC | ||
| N/A | $30.0m Valuation: $114m | IPO | |
$10.0m | Post IPO Equity | ||
$700m | Post IPO Equity | ||
* | N/A | $450m | Post IPO Equity |
$800m | Post IPO Equity | ||
* | $750m | Post IPO Debt | |
* | N/A | $900m | Post IPO Convertible |
| Total Funding | €36.5m | ||
Recent News about Alnylam Pharmaceuticals
EditAlnylam Pharmaceuticals, Inc. is a biotechnology company that focuses on developing RNA interference (RNAi) therapeutics. RNAi is a biological process where RNA molecules inhibit gene expression, effectively silencing targeted genes. This innovative approach allows Alnylam to create treatments for a variety of genetic disorders.
The company primarily serves patients with rare genetic diseases, including conditions like acute hepatic porphyria, amyloidosis, and primary hyperoxaluria type 1. Alnylam operates in the biopharmaceutical market, which involves developing and commercializing drugs based on biological molecules.
Alnylam's business model revolves around research and development (R&D) of RNAi-based drugs. They invest heavily in clinical trials to ensure the safety and efficacy of their treatments. Once a drug is approved, they either market it directly or partner with other pharmaceutical companies to distribute it. For example, they have partnered with the Taiba Group to commercialize their products in the Gulf States.
The company generates revenue through the sale of its approved drugs, licensing agreements, and strategic collaborations. For instance, Alnylam entered a $2 billion strategic financing collaboration with Blackstone to advance their RNAi therapeutics pipeline. Additionally, they offer genetic testing and counseling services, which help identify patients who could benefit from their treatments.
Alnylam's financial health is supported by a combination of product sales, partnerships, and strategic investments. They regularly update investors through press releases, earnings presentations, and annual reports. The company is publicly traded, and its stock information is accessible to investors.
In summary, Alnylam Pharmaceuticals is a pioneering biotech firm specializing in RNAi therapeutics, serving patients with rare genetic disorders, and generating revenue through drug sales, partnerships, and strategic investments.
Keywords: RNAi therapeutics, genetic disorders, biopharmaceutical, clinical trials, drug development, partnerships, revenue, genetic testing, rare diseases, biotechnology.